Mouse models that recapitulate the full phenotypic spectrum of a psychiatric disorder, such as schizophrenia, are impossible. However, a more piecemeal recreation of phenotypic components is feasible and promises to harness the power of animal models using approaches that are either off limits or confounded by drug treatment in humans. In that context, animal models will have a central and indispensable role in the process of discovering the causes of psychiatric disorders and generating novel, mechanism-based treatments. Here, we discuss current approaches used to generate animal models of psychiatric disorders, address the different components of these disorders that can be modeled in animals, and describe currently available analytical tools. We also discuss accumulating empirical data and take an in-depth look at what we believe to be the future of animal models made possible by recent advances in psychiatric genetics.
Introduction
Eradicating the pain and suffering caused by mental illnesses depends on discovering their causes and using this knowledge to generate and screen mechanismbased treatments and, ultimately, for prevention. Animal models will have an indispensable role in this process. What remains a critical challenge, however, is harnessing such model organisms to understand and manipulate predisposing causal factors underlying uniquely human disorders. In this review, we describe the different components of psychiatric disorders that may be modeled in animals, we discuss the strengths and weaknesses of current approaches used to generate these models, and we take a more in-depth look at what we believe to be the future of animal models made possible by advances in psychiatric and molecular genetics. For this reason, we restrict our discussion mainly to rodent, especially mouse, models that are amenable to genetic manipulation. For the sake of clarity and simplicity, we focus primarily on animal models of schizophrenia because of the recent advances in schizophrenia genetics and the multitude of rodent models that are available. However, our discussion is, in principle, relevant to psychiatric disorders in general. For a more detailed description of schizophrenia, see the review in this issue of Neuron by Ross et al. (2006) .
Can Mouse Models of ''Uniquely Human Disorders'' Be Valid?
Generating bona fide mouse models for schizophrenia and most human psychiatric disorders is complicated by several empirical and theoretical reasons. The structural variation and functional divergence apparent during hominid brain evolution reflects the orchestration of genetic networks (Carroll, 2003) and is likely the result of changes in the spatiotemporal expression patterns of regulatory genes. Therefore, when modeling a susceptibility gene in mice, we need to consider the possibility that this gene is ''used'' differently in the unique contexts of the human and mouse brains. A mutation in such a gene may, thus, affect brain function or behavior in the two species in a dissimilar fashion. The validation and analysis of animal models is further complicated by the uncertainty regarding the actual clinical features of the human disorder and its diagnostic criteria. Considerable heterogeneity exists among the symptoms of individuals sharing a common diagnosis, as well as substantial overlap between symptoms of individuals with different diagnoses (Taylor, 1992) . Finally, in comparison to neurodegenerative diseases like Alzheimer's disease or amyotrophic lateral sclerosis, where there is a welldefined neuropathology, neuropathological markers are not readily apparent in most psychiatric disorders, thus further complicating the validation and analysis of animal models. These limitations define the difficulties we face, argue for a more piecemeal recreation of the disorder's components, and highlight the need for a hierarchical approach to their validation. In that respect, the validity of any animal model will depend on the exact syndromic component the model is attempting to capture and the ultimate goal of the model (Geyer and Moghaddam, 2002; Robbins, 2004) . Moreover, the utility of any animal model will critically depend on the experimental level of analysis, with a multilevel approach more likely to identify novel features and allow their further scrutiny.
If Only They Could Talk: Multilevel Analysis of Mouse Models
Traditionally, animal models of psychiatric disorders are analyzed through behavioral assays. Skepticism toward these animal models arose from their obvious inability to convincingly model hallmark features of human psychiatric disorders, such as delusions, hallucinations, or depression. It is important to emphasize, however, that mechanistic insights into the nature of the deficit under investigation cannot be achieved by behavioral assessment alone. Rather, a combined approach that begins at the behavioral level and culminates at the cellular and molecular levels is needed. Whatever the level of analysis, it is still necessary to choose the appropriate phenotypic endpoints to serve as the dependent measures. Since we are unlikely to capture the entire clinical syndrome in an animal model, focus has shifted onto individual behavioral, physiological, anatomical, or biochemical endpoints. These endpoints are conceptualized by the notion of the endophenotype: heritable phenotypic indicators that reflect discrete components of pathophysiological processes more proximal to particular sets of predisposing genes than the actual clinical diagnosis (Gottesman and Gould, 2003) . These discrete endpoints are more amenable to model in animals than the fully expressed clinical manifestation of a psychiatric disorder. They thus provide a more effective approach to identifying neurobiological underpinnings of human psychopathology.
Behavioral Level Approaches
In schizophrenia, different symptom types and disease endophenotypes can be modeled with varying degrees of validity (Table 1) .
Modeling Positive and Negative Symptoms
Finding animal correlates of the positive symptoms of schizophrenia (symptoms ''added'' to the normal experience, such as paranoid delusions, hallucinations, and disordered speech and thinking) is obviously challenging. Nevertheless, hyperactivity in response to stress or novelty and hypersensitivity to psychostimulants have been suggested as useful correlates that can be modeled in rodents and have been extensively used in the validation and assessment of pharmacological models (Geyer and Moghaddam, 2002) . Less extensively modeled are the negative symptoms (symptoms ''subtracted'' from the normal experience, such as blunted emotional expression, low motivation, and social withdrawal), which contribute significantly to poor functional outcome. These symptoms represent a significant portion of the psychopathology in major depression and, considering the substantial comorbidity between schizophrenia and depression, many of these deficits may be secondary symptoms in schizophrenia (Ellenbroek and Cools, 2000) . Impaired social interactions in animals are often used to model negative symptoms of schizophrenia, but the validity of this approach is questionable (see below). Another negative symptom often modeled is anhedonia (loss of pleasure in once pleasurable activities), which is assessed by changes in the reinforcing value of drugs of abuse or natural rewards . Anhedonia, however, is more common to depression and has not been exploited to discriminate between primary and secondary symptoms in animal models of schizophrenia. A detailed description of approaches used to model depression in mice that may be useful in modeling negative symptoms in schizophrenia is provided in an excellent review by Cryan and Holmes (2005) .
Modeling Cognitive Deficits
In addition to positive and negative symptoms, it has become increasingly clear that morbidity in schizophrenia is seriously affected by cognitive deficits, especially in tasks that require executive function, working memory, or attention (Green et al., 2000; Green and Nuechterlein, 2004) . Despite their complexity, these cognitive processes are not uniquely human and can be directly assessed in animals.
Attention, working memory, and executive function are frequently impaired in patients with schizophrenia, irrespective of their level of general intelligence; exist prior to or at the onset of the illness; and persist during both active and remitted phases and during treatment with antipsychotic drugs (Cannon et al., 2000; Elvevag and Goldberg, 2000) . They are also affected in a portion of their nonschizophrenic, first-degree relatives (Cannon et al., 1994 (Cannon et al., , 2000 Saykin et al., 1994) . Based on these and other observations, it has been suggested that problems in these cognitive domains lie at the very core of the disorder (Elvevag and Goldberg, 2000; Green and Nuechterlein, 2004) . However, within-patient heterogeneity in neurocognitive performance and the existence of some patients with apparently normal cognitive performance has been noted in some studies (Brewer et al., 2005; Kremen et al., 2000; Palmer et al., 1997) . Importantly, the National Institute of Mental Health (NIMH) has recently established the Measurements and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative to facilitate the development of new drugs for the cognitive deficits of the disorder. This effort highlights the critical need for robust preclinical assays of cognitive function that more closely relate to neuropsychological tests in order to facilitate translational research (Hagan and Jones, 2005; Jentsch, 2003) .
Modeling Attention Deficits
The concept of attention is multifaceted and includes the allocation of psychological resources to a specific stimulus or task and can be reflexive or deliberate (Colby and Goldberg, 1999) . Preattentive processes tend to be automatic and rapid and to operate outside of conscious awareness, whereas deliberate attentional processes have limited resources, are effortful, and operate more slowly. A common measure of preattentive processing is prepulse inhibition (PPI; Table 2 and Figure 1A ) in which a brief, low-intensity acoustic stimulus (the prepulse) inhibits the reflex caused by a loud stimulus, and it has been discussed extensively in the literature (Geyer, 2006; Geyer et al., 2001; Swerdlow et al., 2001 ). This paradigm is widely used because the assays can be administered to animals with relative ease and in a fashion almost identical to humans.
In clinical populations, controlled attentional function is often assessed using a continuous performance task (CPT) (Riccio et al., 2002) , which includes measures of vigilance, response inhibition, and signal detection. Subjects are shown a series of letters and are instructed to respond to a rare target, like the letter ''X,'' and to withhold responding to all other letters. In a complementary version that may be more sensitive to prefrontal function (Javitt et al., 2000) , the AX-CPT, subjects Neuronmust only respond in the appropriate context, when the target is preceded by an ''A'' and not a ''B.'' An operantbased rodent analog, the 5-choice serial reaction time task (5-CSRT; see Table 2 ), has been developed and extensively validated by the common neural circuits and neurochemical modulation shared across species (Chudasama and Robbins, 2004) . This task requires the animal to monitor, detect, and respond with a nose poke to brief visual targets that are presented at one end of an operant chamber (Table 2 and Figure 1B) . The animal must also learn to resist responding at inappropriate times, and thus measures of response control, inhibition, and impulsivity can similarly be assessed. Although this task was originally designed for rats, it is now used for mice as well but requires months of training to obtain a sufficient level of performance. Nevertheless, by manipulating task parameters such as the duration and frequency of the targets and the time between target presentations, the complex cognitive processes that contribute to performance can carefully be parsed.
Another widely used measure of ''attentional'' functioning in animal models of schizophrenia is latent inhibition (LI) ( Table 2) , and this paradigm has also been (Escobar et al., 2002; Gray and Snowden, 2005; Lubow, 2005) . Briefly, when a novel stimulus or cue is presented repeatedly without any consequence, subsequent association of that cue with an unconditioned stimulus is impaired. Thus, it takes longer to learn that a light signals the availability of food when the light was previously presented alone.
There is debate about what the actual constructs underlying this phenomenon are, whether it is an inability to disengage attention to irrelevant stimuli or to form associations between the cue and the context in which it is presented. Nevertheless, it is important to note that one major advantage of this phenomenon is that impaired LI leads to an enhancement of learning the stimulus association and thus cannot be explained by general performance deficits. Moreover, like PPI, it is relatively high throughput compared to the 5-CSRT and can be readily implemented in mice.
Modeling Memory Deficits
Schizophrenia patients display various forms of memory deficits including impaired working and episodic memory. Working memory is usually defined as the ability to maintain and manipulate information transiently in the service of other cognitive processes to guide behavior (Baddeley, 1992) . Working memory deficits in schizophrenia were first directly characterized using a visual delayed response task (Park and Holzman, 1992) . In this test, subjects are asked to fixate their gaze at a central point while a target is flashed at a fixed location within their visual field. They must continue fixating until the end of a delay, at which point they must shift their gaze to the location of target presentation. More recently, tests that manipulate working memory load (the amount of information held ''online'') and that require manipulation of this information have also been used. There are numerous working memory tasks employed in animals, and their validity and relationship to each other as well as common problems in their implementation have recently been reviewed (Castner et al., 2000; Dudchenko, 2004) . One common task that bears resemblance to the delayed response task is the delayed nonmatch to position (DNMTP) task, which can be administered in an operant chamber or maze (see Table 2 and Figure 1C ). Initially, during a ''sample'' phase, the subject is exposed to a lever, visual target, or arm in a maze. Then, after a variable delay, in the ''choice'' phase the subject must select between the original sample (the ''match'') and the target (the ''nonmatch''). The implementation of this task varies widely between laboratories, most notably in the time between the sample and choice phases and in between individual trials. In humans, working memory spans mere seconds, but many animal studies require the retention of information over substantially longer periods of time. Alternative approaches to working memory that exploit the animal's natural tendency to forage are also used and can require less training than operant-based tasks. The same general strategy can be used in either the holeboard discrimination (Kuc et al., 2006) or radial arm maze tasks (Floresco et al., 1997 ). In the holeboard task, the location of a limited number of food rewards stays constant within 16 choice holes of an open field, and the number of times the subject returns to previously visited and never-baited holes is recorded. Similarly, in a version of the radial arm maze (see Figure 1C) , the subject is given a sample phase of four baited arms (A) Prepulse inhibition (PPI) is often used to measure sensorimotor gating in humans and animals. In response to a loud noise, the subject exhibits a quantifiable, reflexive startle response. If, however, a brief, low-intensity acoustic prepulse precedes the loud noise, the startle response is diminished. The magnitude of change is expressed as percent PPI, with smaller percent changes thought to reflect deficits in sensorimotor gating. (B) Operant chambers may be used to assess a wide array of cognitive functions in rodents, including working memory and attention. One of the most well-developed tasks relevant to many psychiatric disorders is the 5-choice serial reaction time task (5-CSRT). This task requires the subject to monitor, detect, and respond to brief flashes of light. The interval between target flashes and the duration of the target can be varied to change the difficulty of the task. In addition to attention, such tasks can measure vigilance, impulsivity, and response control. (C) Examples of behavioral tasks in relation to the relative dependence on frontocortical (PFC) versus hippocampal (HPC) regions. In general, the longer the retention interval of information, the less the frontal cortex is challenged and the more the hippocampus is recruited. This is only an approximation, and there are no clear cutoffs between different psychological processes or forms of memory. The engagement of different brain regions and types of memory probed depend on the exact task parameters and contingencies, and different mazes may be used interchangeably. We provide only one example of how each may be used. Behavioral flexibility is a form of executive function and measures the ability to discriminate between and associate one stimulus dimension (e.g., color) with reward, then shift the association to another stimulus dimension (e.g., texture). Spatial working memory performance measures the ability to transiently remember information to guide behavior and can be indirectly probed by forcing a run in a T maze (red arm) and after a variable delay (e.g., 5-30 s), allowing access to both the correct, ''nonmatch'' (green) and incorrect arm (red). Short-term spatial memory can also be assessed by the ability to remember the location of four open arms that change day to day in a radial arm maze and after a variable delay (e.g., 30 min to 2 hr) forage for reward in the previously unvisited arms. Longterm reference memory can be measured by the ability to remember the location of a hidden platform in a fixed location of the Morris water maze after 24 hr, 1 week, or longer since the last training session.
Neuronand must recall, after a delay, which arms were originally baited when given access to all eight arms.
In addition to working memory deficits, schizophrenia patients exhibit marked impairments in episodic memory (Aleman et al., 1999) , the ability to recall the time and place of past events (''what,'' ''when,'' and ''where'') . Whether nonhuman animals have episodic-like memories is the subject of increasing debate (Clayton et al., 2003; Hampton and Schwartz, 2004) , but the presence of long-term, declarative-like memory is not controversial. A common measure of short-term episodic memory in clinical studies is the ability to remember a list of words. After a delay of minutes or a day, subjects are asked to either freely recall the words, are given some of the original words and asked to recall the others, or are asked to identify which words in a new list were present in the original. Schizophrenia subjects are most impaired in free recall, and this is thought to result from reduced connectivity of parahippocampal regions (Talamini et al., 2005) . In one relevant rodent task (Table  2 ), a ''list'' of discrete odors is presented in a serial manner separated by minutes. Then, during probe trials, two odors are presented and the subject must select the odor that came either earlier or later in the series. Successful performance in this task depends on the hippocampus and is independent of spatial cues or recognition (Fortin et al., 2002) . Other tasks that have episodic-like components involve remembering the time and location of specific food rewards in a radial arm maze (Babb and Crystal, 2006) or prospective and retrospective information in a cross maze (Ferbinteanu and Shapiro, 2003 ) (see Figure 1C for maze configurations). This avenue of memory assessment remains relatively unexplored in animal models of psychiatric disorders but offers a novel addition to traditional tests of hippocampal function and may have more clinical relevance.
Modeling Executive Function Deficits
Functional integrity of the prefrontal cortex is particularly compromised in schizophrenia and can manifest as deficits in executive functions. These are typically seen as ''higher-order'' cognitive processes that play a supervisory or controlling role over several cognitive domains. They can be related to response control, inhibition, rule switching, planning, problem solving, and general cognitive flexibility. A traditional measure of executive function in patients is the Wisconsin Card Sorting Task (WCST). In this test, subjects are presented with a deck of cards that vary by the type (e.g., circles, squares, or triangles), the number, or the color of the shapes shown. The subject must sort the cards based on one stimulus dimension without knowing which one and use only feedback from the experimenter. Once the rule is acquired, the experimenter changes the rule without notifying the subject. A rodent assay of executive function, attentional set shifting (Birrell and Brown, 2000) (Table 2) , has gained rapid popularity due to the relative ease of its implementation. In this task, subjects are trained to dig in bowls for food rewards that are paired with different digging media or odorants. During the first phase, the subject must learn that food is associated with particular odorants irrespective of digging media. In the second phase, the subject must then learn that food is associated with particular digging media irrespective of odorants, an extradimensional shift. The advantage of this task is that it is very similar to the WCST and requires only 1 day of testing, but it may take hours for a single mouse to complete. The order of associated dimensions can present an additional problem, given that some sensory modalities, like odor, may be more easily associated with food than others.
Ethological Approaches
Debates concerning the best methods in assessing animal behavior began with the founding of ethology a century ago, and they continue today (Gerlai and Clayton, 1999; Sarter and Berntson, 1999) . Recently, there has been a revival of interest in ethological approaches, especially in the assessment of animal models of psychiatric disorders (Crabbe and Morris, 2004; Tecott and Nestler, 2004 ). The rationale is that monitoring spontaneous behaviors (such as foraging strategies, social organization, and diurnal patterns of activity) in ''naturalistic'' settings can reveal deficits that would not be apparent in more traditional laboratory tasks. Practical approximations to natural environments are often performed in laboratory conditions that are sufficiently similar so that the animal could behave as if it were in its natural, ancestral habitat. Ethological approaches have not been widely used or validated in research of animal models of human psychiatric disorders. One of the few uses of ''ethological'' approaches in psychiatric research are the smaller scale studies by Waddington and colleagues that involve sampling, over an extended time frame, of individual elements of behavior in the mouse repertoire, such as sniffing, locomotion, rearing behavior, sifting, grooming, chewing, jumping, and stillness (Waddington et al., 2005; O'Tuathaigh et al., 2006) . These studies may provide useful insights when examining, for example, how a given strain, mutant in a susceptibility gene, affects behavior over the prolonged course of interaction with the environment and under various pharmacological challenges. It is worth pointing out here that human neuropsychological tests, designed to probe specific psychological processes, are not in any way ethological in the sense that they do not consider behaviors in either our ancestral or modern environments. They nonetheless have predictive power over functional outcome in the real world. Thus, ethological approaches may complement, but not replace, current measures of animal cognition that have arisen from the merger of experimental and clinical neuropsychology. Some General Considerations Regarding Choice, Implementation, and Interpretation of Behavioral Tests Ideally, the most important criterion in choosing tests appropriate to model a clinical syndrome and interpreting their results is the conservation of neural circuitry underlying a given behavior (Brown and Bowman, 2002; Robbins, 1998) . It is important to emphasize, however, that the underlying neural circuitry for the behaviors described above are relatively complex and often not well characterized, and therefore it is not always possible to select appropriate behavioral tests that allow meaningful interpretations. Assays of social interactions and PPI provide relevant examples. Social and mating behavior in mice depends, to a large extent, on olfaction. Manipulations, whether pharmacological or genetic, that alter these behaviors may exert their effects through olfactory processing and may have little to do with the clinical deficits. In fact, social withdrawal in patients may arise from general anhedonia, anxiety, and/or social cognitive deficits (Green et al., 2005) . Thus, without knowing the underlying neuronal circuitry of the behavior or symptom and the causes of any dysfunction, the animal model is left simply with superficial similarity to the disease (Robbins, 1998) . This limits the immediate utility of ethological approaches that monitor the social behavior of rodents as a model of human social dysfunction. PPI is one of the best, if not the best, characterized behavioral trait at the neural systems level and is modulated by complex neural circuits spanning a large array of brain regions . The underlying circuitry is so complex, however, that it is not always clear, in the absence of corroborating evidence, whether the deficits are due to pathophysiological mechanisms shared with schizophrenia. The same limitations will certainly apply to other behavioral assays, and because of this, a well-defined framework for assessing the relevance of a given behavioral paradigm to schizophrenia (or any other psychiatric disorder) based on the underlying neural circuits is not yet available. Until this is accomplished, an emphasis needs to be placed on converging evidence from multiple tests designed to measure the same physiological process, psychological construct, or affective state and on judiciously manipulating task contingencies within a single test to control for confounding sensory or motor deficits. For example, working memory performance may be assessed in a Y maze, T maze, cross maze, radial arm maze, and even a Morris water maze (see Figure 1C) . These tasks will vary in the amount of training required, the level of difficulty, and whether they are appetitively or aversively motivated. Moreover, even for a single task, the exact task parameters will determine the extent to which different brain regions are engaged. If working memory is truly affected, however, deficits should not be restricted to one particular task. The disadvantage with such practices is that they are time consuming, labor intensive, and require sufficient knowledge of experimental psychology and animal behavior for appropriate analysis and interpretation of findings.
Another consideration has to do with whether a standard set of tests should be performed in the initial stages of characterizing an animal model of a psychiatric disorder. Indeed, development of a consensus, standardized battery of tests has been proposed as a remedy to the lack of standardized procedures for measuring specific behaviors, an issue that has frustrated many and impeded crossvalidation across studies (Floresco et al., 2005; Tecott and Nestler, 2004) . Even if such a consensus battery of tests is achieved, this does not guarantee a solution, because behavioral tasks conducted under identical protocols can still yield conflicting results depending on the laboratory environment. This is especially true for small effect outcomes (Crabbe et al., 1999; Wahlsten et al., 2003) , which are likely when manipulating a single predisposing allele in genetic animal models. One proposed solution to this problem is the development of automated and high-throughput systems to track a suite of behaviors and then use information technologies to identify behavioral repertoires that rely on specific neural circuits and respond to selective pharmacological agents (Tecott and Nestler, 2004) . These approaches offer obvious advantages in screening candidate therapeutic compounds and in largescale mutagenesis screens. As noted by Crabbe and Morris (2004) , however, whether data collected automatically are less variable than data collected manually has not been established experimentally. In addition, it is hard, at present, to envision how some of the more sophisticated schizophrenia-relevant cognitive tests outlined above can be efficiently adapted to fit within an automated, high-throughput context. Apart from the technical issues, batteries of tests or batteries of analyses are, for the most part, nonhypothesis driven and ''agnostic'' as to the effect of a given experimental manipulation. This leads to the need of statistical corrections for multiple comparisons, especially when there are multiple dependent measures for each behavioral assay, but these are rarely performed in behavioral screens. Despite these caveats, in the case where the biology of a gene is uncertain, standardized batteries of tests may be the only option and are not without merit. Indeed, they can offer a starting point and general guidance toward potentially affected behavioral domains. Any significant effects, however, need to be systematically followed up in a direct and rigorous manner with more specific tests.
An alternative and preferable approach to phenotyping an animal model, especially genetic models of susceptibility genes, is a hypothesis-driven approach that takes into consideration the biology and function of the gene in question (such as expression patterns, contribution of genetic variants to specific endophenotypes in patients and healthy volunteers). Thus, although many behavioral tests may be time consuming, specific hypotheses about what neural circuits and psychological constructs are likely affected will direct the selection of initial tests. Finally, it is worth pointing out here that, due to recent advances in human genetics and the generation of an increasing number of reliable etiological models, the role of behavioral assays is likely to shift, over the next several years, from primarily model validation to providing mechanistic insights into the nature of the genetic factors under investigation. In this context, insights will be provided by a combined approach that includes not only behavioral assessment, but also systems, cellular, and molecular level approaches. These latter approaches, which are only briefly outlined below due to space constraints, hold great promise for novel breakthroughs in psychiatric research.
Systems Level Approaches
Approaches at this level are feasible because, despite the extensive neuroanatomical divergence between mice and humans, particularly the considerable expansion of the frontal cortex (which is especially affected in schizophrenia), the basic layout of fundamental neural circuits between cortex and well-conserved, subcortical structures remains largely intact. The imminent availability of etiological models combined with the advent of rodent neuroimaging and recording technologies will greatly facilitate the identification of brain regions affected by a given etiological factor and will also allow delineating the interactions among regions affected in dysfunctional states. For example, several prominent theories of schizophrenia pathophysiology suggest a disconnection between frontocortical and temporal limbic regions of the brain . This can, in principle, be tested using in vivo recordings combined with direct neuronal stimulation of inputs to assess how different brain regions drive the activity of others. Another promising avenue is the use of simultaneous multiunit recordings from interconnected brain regions in awake-behaving animals (Jones and Wilson, 2005; Siapas et al., 2005) . This would allow the disentanglement of proposed desynchrony of neural oscillations among brain regions of patients as they perform cognitive tasks (Green and Nuechterlein, 1999) .
Cellular and Molecular Level Approaches
Approaches at this level are the most upstream from the observed clinical psychopathology, but they have two important advantages. First, molecular and cellular functions of a gene are more likely to be evolutionarily conserved compared to any behavioral outcomes the gene may influence. Second, it is conceivable that the ''closer'' one probes to the primary deficit, the less likely it is that downstream compensatory mechanisms come into play, and the more likely that any resulting functional consequences will be detectable. Therefore, more reductionistic measures could be more sensitive in detecting underlying dysfunctions compared to behavioral outcomes that are multifaceted and perhaps subtler due to the deployment of compensatory mechanisms. Cellular and molecular level approaches can be used to identify the cellular and synaptic substrate(s) underlying the consequences of specific genetic, pharmacological, or neurodevelopmental disruptions or to identify (in a high-throughput fashion) changes in gene expression, protein levels, or posttranslational modifications. These latter approaches, in particular, hold great promise for identification of individual genes, gene pathways, and cellular processes that either serve as direct targets or interact with the disrupted pathways to increase susceptibility to a given psychiatric disorder (Anholt et al., 2003; Mirnics et al., 2003 Mirnics et al., , 2005 . Indeed, recent work in genetic mouse models suggests that some changes in gene expression induced by a mutation could be adaptive in nature and could reduce the penetrance of the primary mutation (Paterlini et al., 2005) . As such, identifying compensatory changes in the brains of mouse models can point to novel, endogenous ''strategies'' developed by the brain to cope with introduced deficits. The involvement of these compensatory genetic pathways can be verified in follow-up human genetic studies and exploited as targets for novel treatments.
Deconstructing Schizophrenia in a Model Organism
To date, animal models of psychiatric disorders have been developed for different goals and have implicitly or explicitly modeled different aspects of the disorder in question. Models of pathophysiology attempt to address the most proximal brain dysfunction that could produce the clinically observed psychopathology. Models that attempt to recapitulate the processes that lead to the pathophysiology of a disorder are models of pathogenesis. Finally, models designed to confirm or identify experimentally probable causal factors in the development of the disorder are etiological models. These have been the most difficult models to produce because very little was known about the root causes of many psychiatric disorders. Recent advances in our understanding of the relevant genetic and environmental risk factors, however, have increased the likelihood of developing such models.
Models of Pathophysiology
These models typically rely on the assumption that, because a psychoactive drug produces a psychopathology similar to that seen in individuals with a certain psychiatric disorder, the neurotransmitter system affected by the drug is dysfunctional in the disorder (Svenningsson et al., 2003 ; see the review in this issue of Neuron by Ross et al. [2006] ). Thus, pathophysiological animal models are usually pharmacological, but, as described below, genetic mouse models have also provided useful insights Glickstein et al., 2002; Kellendonk et al., 2006; Mohn et al., 1999) . Although additional neurochemical systems have been implicated, we will focus on dopamine-and glutamate-based models because these are the most extensively studied.
Animal Models of Dopaminergic Dysregulation
The dopamine hypothesis of schizophrenia has been reviewed extensively (Kapur, 2003) . Simply, this hypothesis postulates excessive dopaminergic transmission in schizophrenia, although the explanatory power of dopamine excess is limited to positive symptoms, as it cannot account for the prominent cognitive and negative symptoms of schizophrenia (Davis et al., 1991) . These limitations led to several refinements and reformulations of the dopamine theory of schizophrenia to include complex reciprocal interactions between dopamine systems leading to deficient cortical and excessive subcortical dopamine (Deutch, 1992; Grace, 1991) . A recent study by Kellendonk et al. (2006) attempted to probe further the basis of the reformulated dopamine hypothesis using an elegant genetic approach. Based on a number of observations linking increased striatal dopamine D2 receptors (DRD2s) and dopaminergic transmission to the pathophysiology of schizophrenia (Abi-Dargham et al., 1998) , these authors created a transgenic mouse line that selectively and transiently overexpressed DRD2s within the striatum of mice. It was found that DRD2 overexpression in the striatum decreases dopamine turnover and increases activation of dopamine D1 receptors within the frontal cortex, factors known to impact working memory performance across species (GoldmanRakic, 1999) . These transgenic mice also exhibit selective behavioral impairments in tasks dependent on the frontal cortex. These deficits persist even after the transgene has been switched off, indicating that it results from excess DRD2 expression during development. Interestingly, despite changes in striatal DRD2 occupancy similar to that observed in patients, these transgenic mice were only modestly impaired cognitively, suggesting that DRD2 dysfunction of the magnitude observed in patients is not sufficient to produce severe cognitive deficits in animal models. The work of Kellendonk et al. (2006) highlights the importance of a circuit-based approach to understanding the pathophysiology of psychiatric disorders. In addition, because this animal model is an extension of traditional pharmacological models of dopamine dysfunction, it may help in the improvement of current pharmacotherapies.
Animal Models of Glutamatergic Dysregulation
The glutamate hypothesis of schizophrenia has also been reviewed extensively elsewhere (Goff and Coyle, 2001; Javitt and Zukin, 1991) . This hypothesis has motivated the generation of a plethora of pharmacological models (Jentsch and Roth, 1999; Moghaddam and Adams, 1998) . Possibly one of the most important contributions of these models was the reconciliation of traditional dopamine models with the mounting evidence of reduced NMDA receptor (NMDAR) function (Jentsch et al., 1997) . In addition to pharmacological models, genetically engineered mouse models have also been employed to study the presumed NMDAR hypofunction in schizophrenia. In one such model, the expression of the obligate subunit, NR1, of the NMDAR was reduced to 5% of endogenous levels in mice (Duman, 2002; Duncan et al., 2002; Mohn et al., 1999) . As expected, these mice showed reduced sensitivity to NMDAR antagonists and demonstrated a ''schizophrenia-like'' phenotype that included decreased social interactions and hyperlocomotion. Many of these abnormal behaviors were ameliorated with antipsychotic drug administration. However, the nature and specificity of any cognitive deficits related to schizophrenia were not assessed.
What both dopamine and glutamate models have in common is that they attempt to account for the most proximal causes of the disease-associated psychopathology. This allows for the generation of symptombased treatments that might offer the best hope for those already diagnosed with schizophrenia (Costall and Naylor, 1995; Coyle and Tsai, 2004; Goff and Coyle, 2001) . It is questionable whether these models on their own will provide insights into the actual causes leading to the pathophysiological state. They may, nonetheless, be instrumental in interpreting results obtained from models of etiology (see below).
Models of Pathogenesis
Several lines of evidence have led to the hypothesis that early developmental insults set the way for abnormal brain development and the later emergence of psychosis (Weinberger, 1995) . At least two widely used animal models, employing early, in utero, or postnatal perturbations that interfere with normal brain maturation, address this possibility. One model employs lesioning the ventral hippocampus of neonatal rats, the brain region homologous to the portion of hippocampus most affected in patients (Lipska and Weinberger, 2000) . This lesion does not produce any obvious behavioral abnormalities in the young pups. During adolescence, however, several behaviors related to schizophrenia emerge. These include increased locomotor response to stress and novelty, supersensitivity to amphetamine (AMPH), and PPI deficits. Many of these behaviors are reversed with exposure to antipsychotics, and adult lesions do not produce similar effects. Another neurodevelopmental model aims to disrupt normal brain development in more subtle ways. In this model, the developing rodent fetus is exposed to a methylating agent at specific time points . Depending on the time window and dosage, adult rats exhibit several neuroanatomical and behavioral abnormalities related to schizophrenia. These include increased cortical neuronal density, supersensitivity to AMPH, and cognitive deficits. Similar to the ventral hippocampal lesion model, the supersensitivity to AMPH does not manifest until adulthood. Because there is no evidence of similar lesions playing a role in the development of schizophrenia, both models lack etiological validity, but they provide useful insights on how abnormal brain development can lead to the characteristic postadolescent manifestation of the disorder and could facilitate generation of novel treatments.
Models of Etiology Environmental Models
Since the early 20th century, several environmental causes of schizophrenia and other psychiatric disorders have been proposed. These include obstetric complications, malnutrition, and viral exposures (Jablensky, 2003) . For example, epidemiological studies show an increased risk for psychosis among children exposed to influenza and other viruses during the second trimester. Subsequent animal models showed that if pregnant rodent mothers are induced to mount an immune response, the offspring grow to show behavioral abnormalities . This is accomplished by injecting a synthetic double-stranded RNA, polyriboinosinic-polyribocytidilic acid (poly[I:C]) that mimics viral exposure and causes release of proinflammatory cytokines in the pregnant mothers. The resulting behavioral deficits in the adult offspring include impaired PPI and cognitive performance as well as increased sensitivity to MK801 and AMPH (Shi et al., 2003) . Other animal models have shown that viral exposure during different developmental periods may lead to diverse psychopathologies (Meyer et al., 2006) , indicating that animal models of etiology will be critical in determining how shared environmental risk factors may give rise to distinct psychiatric disorders. Genetic Models Genetic factors play a prominent role in many psychiatric disorders, and numerous putative candidate genes have been identified (Gogos and Gerber, 2006) . Mouse models of ''susceptibility genes'' identified through human genetic studies hold tremendous promise in understanding the function of a gene and its contribution to disease pathophysiology in the context of tractable cellular pathways, neural circuits, and behavior. They also offer several additional, unique advantages. For example, they allow for the identification of early mutational effects and the study of their developmental progression. In addition, they allow for an efficient and thorough investigation of interactions among susceptibility genes and between genes and environmental factors, all of which underlie the complexity of psychiatric disorders.
There are two predominating hypotheses regarding the genetic architecture of complex psychiatric disorders such as schizophrenia. According to the common disease/common allele hypothesis (Pritchard and Cox, 2002) , no single gene is necessary or sufficient to cause the disease, but instead, common (R1%) variants in more than one susceptibility gene, each contributing a small effect, act in combinations to increase the risk of illness. In that context, a mouse model for an individual candidate gene is unlikely to capture the entire complexity of the disorder. The alternative hypothesis (common disease/rare allele hypothesis) proposes that complex psychiatric disorders may instead result from the effects of many rare but penetrant variants, with substantial allelic heterogeneity at disease-causing loci. Identification of such rare alleles, if they exist, will definitely facilitate modeling efforts, especially when highly penetrant loss-of-function alleles are involved that can be faithfully modeled by simple knockout mouse models. Empirical data suggest that both modes of inheritance may operate for at least some risk genes. For example, both common and rare variants were identified in two leading candidate genes, proline dehydrogenase (PRODH) and Disrupted-in-Schizophrenia 1 (DISC1) (Gogos and Gerber, 2006) . Unexpectedly, natural variants that closely mimic the human counterparts were also identified in mouse orthologs of these two genes, providing a unique opportunity to model the consequences of the human disease variants (Gogos et al., 1999; Koike et al., 2006) . These are likely fortuitous exceptions, however, and sophisticated gene-targeting strategies will be required to generate models for the majority of susceptibility genes. In that respect, there are several important factors that need to be considered for the generation of such models and for the design and interpretation of their analysis, and some general guidelines are provided below.
The Functional Significance of a Risk Allele
The most important consideration in developing etiologically valid genetic mouse models has to do with the nature of the disease-associated genetic variants. In the case of complex genetic disorders, the associated variants usually have no obvious effect on protein structure (Rebbeck et al., 2004) . To complicate things further, these genetic variants may only serve as proxies for physically linked, true risk variant(s) residing within the identified gene or a nearby gene (linkage disequilibrium) (Newton-Cheh and Hirschhorn, 2005) . Finally, few of the disease-associated variants are expected to be null alleles, and therefore it is highly unlikely that a knockout mouse model with a global and persistent neuronal and nonneuronal decrease in the target gene levels will serve as an accurate model of the risk allele. These uncertainties contribute to the challenging task of establishing causality from human genetic association studies and mouse models. Obviously, the minimum amount of information needed is whether the risk allele is a hypomorph or gain of function and therefore whether a mouse knockdown strategy or transgenemediated overexpression, respectively, can model it accurately. Additional desirable information would be whether the risk variant affects, for example, splicing or expression in specific brain areas, cellular populations, or developmental stages. The Effect of Pleiotropy A related consideration has to do with the wide expression and pleiotropic effect of many targeted genes. Given such pleiotropy and complexity, in the absence of reliable information on the nature of the predisposing allele, one needs to consider carefully when modeling such genes using mouse knockout approaches which of a large number of alternative phenotypes is a critical link between the disease-related genetic risk variant(s) and susceptibility to the specific psychiatric disorder.
Recent results from two leading candidate genes help illustrate some of the relevant difficulties of translating human genetic findings into informative animal models of predisposing genetic factors. Neuregulin-1 (NRG-1) is a leading candidate susceptibility gene for schizophrenia (Stefansson et al., 2002) . Nrg-1 knockout mice, lacking various domains of the gene, have been extensively used to understand the broad deficits in neuronal migration and neurite outgrowth, glial cell proliferation, and cellular signaling induced by impaired Nrg-1 function (reviewed in Corfas et al. [2004] ). These same mice show, among other phenotypes, decreased expression of NMDA receptors, impaired PPI, and deficits in LI as well as changes in exploratory behavior and habituation in ethologically based assays (Rimer et al., 2005; Stefansson et al., 2002) . The functional implications of the NRG-1 genetic variation related to schizophrenia, however, are unclear, and a recent study on human postmortem tissue seems to indicate that NRG-1 signaling may be enhanced in some individuals with schizophrenia (Hahn et al., 2006) . Thus, although the mouse studies summarized above provide insight into the basic function of NRG-1, whether a knockout mutation can model the relevant clinical aspects of its genetic contribution is arguable and the subject of ongoing investigation (Hashimoto et al., 2004; Law et al., 2006; Petryshen et al., 2005) .
Brain-derived neurotrophic factor (BDNF) is a leading candidate susceptibility gene for bipolar disorder, obsessive-compulsive disorder, and possibly schizophrenia. BDNF participates in practically all aspects of brain development, maturation, and function. The function of this gene has been extensively studied using a variety of constitutive as well as spatially and temporally restricted knockout mice (Akbarian et al., 2002; Chourbaji et al., 2004; Gorski et al., 2003; Kernie et al., 2000; Lyons et al., 1999; Monteggia et al., 2004) . It is unclear, however, how accurately these studies model the genetic contribution of the gene. Indeed, recently, a primatespecific Val66Met functional missense polymorphism in the coding region of the BDNF gene that appears to regulate BDNF trafficking to synaptic sites and depolarization-dependent secretion has been identified. This polymorphism was shown to modulate the risk of a number of psychiatric disorders (Geller et al., 2004; Hall et al., 2003; Sklar et al., 2002) as well as a number of related endophenotypes (Egan et al., 2003) , and, intriguingly, some of these studies indicated an unexpected protective effect for the Met66 variant, which causes impaired regulated secretion of BDNF. Thus, modeling impaired activity-induced release of BDNF using humanized knockin mouse models would allow additional and possibly more precise insights into the nature of the contribution of this gene. The Effect of Genetic Background, Environment, and Sex Apart from controlling for the confounding factors outlined above and independent of the modeling approach, several recent findings highlight the importance of defining and controlling genetic backgrounds, environmental variables, and sex when developing and analyzing genetic models of psychiatric disorders (Cabib et al., 2000; Crabbe et al., 1999; Gerlai, 1996) . In particular, the genetic background onto which a mutation is backcrossed can affect the detection of a phenotype in a mutant mouse. This may result from a nonoptimal baseline level of behavior in wild-type control animals. For example, different inbred strains manifest variable levels of PPI (Dulawa and Geyer, 2000; Logue et al., 1997; Paylor and Crawley, 1997) . Among some of the most commonly used strains, both C57BL/6 and 129Sv strains demonstrate PPI (although C57BL/6 shows reduced PPI levels compared to the 129Sv), whereas the DBA/2 strain shows little, if any, PPI and therefore represents an undesirable genetic background for the examination of a mutation that might reduce PPI. Similar background-dependent variability has been reported in other relevant cognitive behavioral tasks, including habituation (Dulawa and Geyer, 2000) , the Morris water maze, and fear-conditioning tasks , as well as in continuous alternation tasks (Gerlai, 1998) . The effect of genetic background is task specific, and therefore there is no ''best'' strain that can be recommended across all behavioral tasks. Instead, the genetic background should be chosen based on the postulated effect of a given mutation on elevating or reducing the behavioral phenotype under scrutiny . Complications may also arise from the undesirable contribution from flanking genes derived from the ES cell donor strain (discussed in detail by Crusio [2004] ), as well as from complex functional interactions between the mutation and background genes that may mask the effect of the introduced mutation (see also below). Indeed, the recent finding that one of the most widely used mouse strains carries a mutation in Disc1 (Koike et al., 2006) , a leading schizophrenia candidate gene, underscores even further the importance of controlling the genetic background when modeling genes predisposing to schizophrenia and related psychiatric disorders. In addition to genetic background, controlling for laboratory environmental variables is also important, especially regarding the reliability and reproducibility of relatively subtle behavioral effects. This issue is discussed in great detail in Crabbe et al. (1999) and Wahlsten et al. (2003) . Finally, experimental studies of mouse models have traditionally included exclusively male subjects, in an effort to control for the potentially confounding hormonal effects during the estrous cycle in females. However, given the accumulating evidence for gender-specific genetic effects on the risk and course of psychiatric diseases as well as on the severity of their symptoms (Hafner, 2003; Hennah et al., 2003) , it is advisable that analysis be carried in animals of both sexes.
Accumulating Empirical Data
In the past 4 years, significant advances in susceptibility gene discovery have taken place fueled by the complete sequencing of the human genome, the availability of high-throughput genomic analyses, and the generation of new analytical and bioinformatics tools. Several candidate susceptibility genes have been identified, each supported by varying degrees of evidence (Gogos and Gerber, 2006) . These recent advances in gene discovery have started bearing fruit, and the first genetic mouse models of susceptibility genes have emerged.
Constitutive or Conditional Knockout Models
For the most part, genetic mouse models have been limited to constitutive or conditional knockouts. These models are summarized in Table 3 as well as in recent reviews by Chen et al. (2006) and Powell and Miyakawa (2006) . Although they do not necessarily reproduce the risk alleles and therefore have limited etiological validity, these models should contribute to our efforts to identify candidate genes and understand their general function, as well as to identify the genetic pathway(s) they participate in. In addition to the Nrg-1 knockout mice described above, another relevant example is provided by a conditional knockout of the gene encoding for the calcineurin-regulatory subunit. These mice demonstrate several schizophrenia-related phenotypes, such as deficits in working memory and PPI , and thus implicate the calcineurin-signaling pathway in the pathogenesis or pathophysiology of schizophrenia. Although variants in this gene have not been shown to increase risk for schizophrenia, another gene in the pathway (PPP3CC) has been identified as a potential susceptibility gene .
Mice deficient in the gene encoding for Akt1 provide an additional example. A greater sensitivity to the disrupting effects of AMPH on PPI was initially observed in an Akt1-deficient mouse model (Emamian et al., 2004) . This observation, along with evidence for a decrease in AKT1 protein levels and substrate phosphorylation levels in brains and lymphocytes of some individuals with schizophrenia (Emamian et al., 2004) , implicated the AKT1 signaling pathway in the neurobiology of schizophrenia. Subsequent analysis confirmed an association between schizophrenia and AKT1 genetic variants (Emamian et al., 2004; Schwab et al., 2005) and also showed that AKT is a key signaling intermediate downstream of DRD2, the best-established target of antipsychotic drugs (Beaulieu et al., 2005) .
Mouse Models that Mimic Putative Risk Alleles
In addition, a small number of mouse models have recently appeared that closely mimic putative risk alleles identified by human genetic studies. Although the level of analysis of these models is in early stages, such mouse models hold great promise for testing the general utility of accurate genetic mouse models of psychiatric disorders. Moreover, they will be instrumental in designing an efficient framework for analyzing additional etiologically valid genetic mouse models that are likely to appear in the next few years. Importantly, these models are based on rare genetic lesions strongly linked to psychiatric disorders and circumvent the uncertain nature of some genetic association studies. They thus are more likely to have etiological validity. Despite the fact that these models are based on rare genetic events, they nonetheless may help identify cellular pathways and neural circuits dysfunctional in schizophrenia in general. Empirical data from these models are summarized below. Mouse Models of the 22q11 Schizophrenia Susceptibility Locus 22q11 microdeletions represent the first unequivocal association between a well-defined genetic lesion and schizophrenia at the population level, accounting for w1%-2% of the disease in Caucasian samples (Karayiorgou et al., 1995) . Notably, individual carriers of a 1.5 Mb deletion in the q11 locus of chromosome 22 (22q11) have an w20-to 30-fold higher risk to develop schizophrenia as compared to the general population . Most of the 27 known genes located within the deleted region are expressed in the brain in a relatively wide pattern. Results of the genetic analysis performed so far suggest that 22q11 microdeletion-associated schizophrenia may have the characteristics of a contiguous gene syndrome where a small subset of the deleted genes (that may interact with each other) dramatically increase disease risk . The syntenic region of the human 22q11 locus, which lies on mouse chromosome 16, includes nearly all human genes but in slightly different order. The robust association between this well-defined genetic lesion and the unprecedented increase in the risk to develop schizophrenia, coupled with the conserved arrangement of the mouse orthologs in the syntenic locus, provides a unique opportunity to generate mouse models with strong etiological validity that are poised to offer novel insights into the neurobiology of schizophrenia.
The 22q11 microdeletion has been modeled in the mouse using chromosomal engineering approaches (Paylor et al., 2001; K. Stark, A. Bagchi, H. Liu, A. Mills, M. Karayiorgou, J.A.G., unpublished data) . Paylor and colleagues (Paylor et al., 2001) showed that mice carrying a deletion that represents only a subregion of the ''schizophrenia critical region'' (Karayiorgou et al., 1995) have deficits in PPI and associative fear memory. In the latter case, the response of these mice suggests that they have difficulty remembering the types of cues associated with a complex training environment for long (24 hr), but not short (1 hr) periods, indicating deficits in hippocampal function (Abel et al., 1997; Le Pen et al., 2000) . More recent work in mice carrying a deletion equivalent to the entire schizophrenia critical region has identified marked cognitive impairments in working memory tasks (W.-S. Lai, K. Stark, M. Karayiorgou, and J.A.G., unpublished data) . These observations indicate that this genetic model may have excellent etiological and face validity.
Single-gene models have also been generated for candidate susceptibility genes from the 22q11 locus. Among them, PRODH is a leading candidate gene (Gogos and Gerber, 2006) identified initially through human genetic studies in families afflicted with schizophrenia (Jacquet et al., 2005; Liu et al., 2002) . It encodes a mitochondrial enzyme that metabolizes L-proline, a putative neuromodulatory amino acid that may influence glutamatergic transmission (Renick et al., 1999) . A Prodh knockdown mouse strain that represents an accurate model of the functional consequences of susceptibility variants described for this gene (Bender et al., 2005) has been established and shows many neurochemical and behavioral features relevant to schizophrenia (Gogos et al., 1999; Paterlini et al., 2005) . Specifically, Prodh deficiency caused a significant enhancement in glutamate release and synaptic transmission at CA3-CA1 synapses. Importantly, in vivo microdialysis revealed increased cortical dopamine efflux in the mutant mice following acute, systemic AMPH administration. In contrast to some human studies showing increased AMPH-induced dopamine release in the striatum of patients with schizophrenia, AMPH-induced striatal, dopamine efflux was normal. Nevertheless, Prodh-deficient mice showed hypersensitivity to the locomotor effects of AMPH, abnormal PPI, and deficits in both hippocampal and amygdala-based forms of associative learning. When tested in a delayed-alternation task, low Prodh activity was not associated with changes in spatial working memory performance. However, deficits in this task emerged in Prodh-deficient, but not wildtype, mice upon pharmacological inhibition of Comt, an enzyme involved in degradation of dopamine and encoded by a schizophrenia candidate gene also located within the 22q11 microdeletion locus. Inhibition of Comt activity also potentiated the effect of AMPH on locomotor activity and induced further deficits in PPI specifically in Prodh-deficient mice, providing the first biological evidence for interaction between two schizophrenia susceptibility genes. This interaction was also reflected at the transcriptional level, with levels of Comt transcript and protein upregulated in the frontal cortex of Prodh-deficient mice. This seems to represent a homeostatic response whereby an increase in Comt expression is engaged to buffer excessive dopamine signaling in the frontal cortex of mice with a hypomorphic variant of the Prodh gene (Paterlini et al., 2005) .
Notably, these animal-model-based predictions found support in recent studies of individuals with 22q11 microdeletions. These studies revealed that, in the context of increased L-proline levels, a low-activity form of the COMT enzyme (Met158) encoded by the nondeleted allele is a risk factor for the development of psychotic symptoms in these individuals (Gothelf et Chourbaji et al., 2004; Egan et al., 2003; Gorski et al., 2003; Kernie et al., 2000; Lyons et al., 1999 Review Other genetic mouse models of candidate susceptibility genes from this locus include knockout mice for Comt (see above) (Huotari et al., 2002 (Huotari et al., , 2004 , Zdhhc8 (a palmitoyltransferase that plays a key role in the assembly of excitatory synapses and dendritic growth) (Mukai et al., 2004) , and Tbx1 (a transcription factor) (Paylor et al., 2006) . Apart from PPI assays, systematic analysis of schizophrenia-related endophenotypes in these mice has not been reported yet. Among them, heterozygous mice deficient for the Tbx1 gene were reported to have robust deficits in PPI (Paylor et al., 2006) , but a more recent study failed to observe such deficits (Long et al., 2006) . Interpretation of this finding, if true, is at present confounded by ample evidence that the Tbx1 gene is involved in the development of the outer, middle, and inner ear (Arnold et al., 2006; Vitelli et al., 2003) , and abnormal PPI is a phenotype expected to emerge as a result of abnormal ear development (Liu et al., 2000) . A Mouse Model of the DISC1 Schizophrenia/Bipolar Susceptibility Locus DISC1 at chromosome 1q42 is one of the leading schizophrenia candidate genes (Gogos and Gerber, 2006; Porteous and Millar, 2006) . DISC1 was originally identified as the gene interrupted by a balanced translocation involving chromosomes 1 and 11 (1q42.1;11q14.3) linked to psychopathology including schizophrenia, depression, and bipolar disorder in a large Scottish family (Millar et al., 2000) . Further association and mutational studies have been supportive but not unequivocal (Gogos and Gerber, 2006; Green et al., 2006) . Kamiya et al. (2005) used electroporation of Disc1 RNAi molecules and a DISC1 cDNA encoding for a dominant-negative protein to functionally deplete mouse Disc1 in utero (E14.5). Postnatally, this manipulation inhibited radial neuronal migration in the cerebral cortex and induced misorientation and shortening of primary dendrites. This finding appears to be consistent with in vitro studies, which have shown that DISC1 forms a complex with NDEL1 and the microtubule-associated motor protein dynein at the centrosome (Kamiya et al., 2005; Morris et al., 2003) . NDEL1 also binds to LIS1, a protein involved in lissencephaly (Feng and Walsh, 2004; Shu et al., 2004) , a neuronal migration disorder causing cortical malformation in humans. As a result, it was suggested that DISC1 is involved in neuronal development, particularly within the cerebral cortex, and that loss of DISC1 function might underlie neurodevelopmental dysfunction in schizophrenia and other psychiatric disorders (Sawa and Snyder, 2005) . Based on in vitro observations that phosphodiesterase 4B (PDE4B) and DISC1 physically interact, Millar et al. (2005) proposed an alternative model of DISC1 action involving regulation of cAMP signaling, a second messenger system known to modulate affect and cognition (Duman, 2002) . When bound to DISC1, PDE4B is inactivated, and it is predicted that decreased expression of DISC1 in patients and mice may result in increased PDE activity and increased inactivation of cAMP. Koike et al. (2006) attempted to generate an etiologically valid mouse model by mimicking the putative effects of the translocation observed in the Scottish family. They used a gene-targeting approach designed to generate a truncated Disc1 transcript, and possibly protein, while at the same time preventing induction of nonsense-mediated decay and keeping the overall level of gene expression within physiological range. They unexpectedly discovered a 25 bp deletion in exon 6 of the mouse gene in the 129S6/SvEv strain, which induces a frameshift in the reading frame and results in premature translational termination. Compared to a variety of strains, the deletion was specific to 129S6/SvEv, although subsequent analysis found that it is widespread among many 129 substrains (P.A.A. and J.A.G., unpublished data) . Genetic association studies in patients with schizophrenia and their unaffected siblings suggest that DISC1 variants might influence working memory performance (Callicott et al., 2005; Cannon et al., 2005) . Koike et al. (2006) used Disc1-deficient mice to ask whether Disc1 deficiency affects spatial working memory performance as assessed in a delayed nonmatch to place task. They found that C57BL/6J mice carrying the genetically modified 129S6/SvEv Disc1 allele (which includes the exon 6 deletion variant as well as an engineered termination codon in exon 8 and a polyadenylation signal in intron 8 [Koike et al., 2006; M. Kvajo, P.A.A., and J.A.G., unpublished data] ) learned the task and performed as well as wild-type littermates during training, but during the working memory test showed a consistent impairment. This deficit was observed in both heterozygous and homozygous mutant mice, although neither showed any changes in locomotor activity or PPI (Koike et al., 2006) . Importantly, for the studies outlined above, the mutant Disc1 allele had to be transferred onto a C57BL/6J genetic background. While this experimental design decreases the probability of contribution in trans of unrelated background genes, it does not address the well-known ''flanking gene problem'' (Crusio, 2004) , thus limiting somewhat the etiological validity of the model in its current form.
It is worth noting that, despite predictions, preliminary analysis of this mouse model by low-resolution histology (Koike et al., 2006) did not reveal the type of changes in brain morphology anticipated by impaired Ndel1 or Lis1 function (Feng and Walsh, 2004; Shu et al., 2004) . The reason for this discrepancy is unclear. Apart from obvious experimental differences and the fact that some isoforms persist in the Disc1-deficient C57BL/6J mice (Koike et al., 2006; Kvajo, P.A.A., and J.A.G., unpublished data) , it could be that under physiological conditions Disc1 deficiency results in subtle effects in neuronal development and migration undetectable by Nissl staining. It is also possible that under physiological conditions, in the absence of Disc1, migration is merely delayed and by adulthood any deficits have been overcome, with all neurons eventually reaching their final destination. Such delayed radial migratory processes may lead to abnormal cortico-cortical connections, indicating that further analyses at the synaptic and electrophysiological levels are needed.
Limitations and Challenges in Interpreting Findings from Genetic Models
Despite their obvious advantages, interpreting results from even the most reliable genetic mouse models with etiological validity can be confounded by at least two factors. First, an ideal one-to-one correspondence between a gene and a modeled endophenotype is unlikely to exist. More likely, one susceptibility gene affects more than one (but not all) modeled endophenotypes, and in turn each modeled endophenotype is affected by more than one predisposing gene (Figure 2A) . Therefore, as already evident in the accumulating empirical data outlined in the previous section, a gene-based model is unlikely to exhibit abnormalities in all schizophrenia-related endophenotypes, and it is expected to recapitulate fewer features of the disorder as compared, for example, to models of pathophysiology and pathogenesis, which are downstream of multiple predisposing genes and thus may affect multiple neural systems and circuits. Second, genetic manipulations are the most upstream from the observed clinical psychopathology and thus, in the context of a model nervous system, may not manifest at the behavioral level and may require multiple manipulations to become fully penetrant at this level ( Figure 2B ). This is important because the effects of a given genetic mutation on a biological trait can be masked by one or more other genetic or environmental factor, and as a result, substantial effects on the phenotype are observed only when there are multiple hits to a disease-related gene network (this phenomenon is also known as epistasis) (Moore, 2005) . The effect of a modeled gene may be penetrant only at the level of synaptic transmission if, for example, efficient homeostatic responses emerge at higher levels, in the form of ''damage control'' ( Figure 2C ). Such buffering processes usually depend on well-orchestrated changes in activity and expression of other genes. In this case, the full effect of a genetic disruption may only be revealed in the presence of genetic or pharmacological inactivation of these genes (Paterlini et al., 2005) , or in the presence of environmental factors that compromise the efficiency of genomic buffering. In all, no single gene model is likely to emerge as representative of the entire disorder, and at best it will reproduce either a subtype of the disorder or a particular aspect of an endophenotype. Elegant, but likely partial, solutions to overcome these limitations can be explored by combined modeling of more than one genetic risk factor. This is the case, for example, for mice carrying the equivalent of the 22q11 microdeletion. It can also be achieved by crossing more than one engineered mouse strain or by employing multiple gene knockdowns using recently developed RNA interference approaches (Yu and McMahon, 2006) . Combined modeling of genetic deficits and environmental influences such as viral infections (Shi et al., 2003) or cannabis exposure (Caspi et al., 2005) offers additional promising solutions in increasing the power and usefulness of genetic mouse models. The effect of targeting a risk gene will vary because different genes may have different effect sizes and thus penetrate at different levels of analysis. With multiple genetic and/or environmental manipulations, the penetrance may be increased such that the animal model will exhibit various behavioral abnormalities that may approach the clinical syndrome. (C) An example of a gene 3 gene interaction whereby the effect of a targeted gene is buffered by homeostatic mechanisms. These compensatory processes are modulated by another gene such that if this gene is disrupted, the penetrance of the primary targeted gene effect will increase to a higher level.
Finally, it is worth noting that our argument thus far in favor of ''etiologically valid'' genetic mouse models is based on the assumption that generation of genetic mouse models of psychiatric disorders follows unequivocal genetic risk variant identification via human genetic approaches. This will be the case for some genes, but it is also likely that for other genes, even under the best of circumstances (e.g., large patient samples and large numbers of markers [Scolnick, 2006] ), the results will remain inconclusive. Such is the ''nature of the beast,'' that the combined phenotypic and genetic heterogeneity of these disorders often limits the power of genetic association studies (Freimer and Sabatti, 2004) . Even in this case, however, generation of accurate genetic mouse models is not without its merits and could be instrumental in balancing statistical genetic findings from human studies and hard biological evidence from mouse studies to establish the ''biological plausibility'' of putative etiological factors. Thus, as better-defined ''blueprints'' for the standardized and systematic assessment of modeled endophenotypes become available, the boundary between human genetic and animal model studies is likely to be blurred. Animal models will not only be imperative in validating and understanding the contribution of susceptibility genes but also in identifying new ones.
Concluding Remarks
Modeling psychiatric disorders in mice is an evolving process that has reached a turning point such that accurate mouse models of candidate susceptibility genes are now becoming feasible. Despite caveats, in the next few years, etiologically valid genetic models are poised to offer breakthroughs in our understanding of the pathogenesis of these disorders. Realization of this promise will depend on at least three important factors: first, on the careful dissection of the underlying genetic complexity of the human disorders; second, on the careful integration of the accumulating genetic findings and the large volume of data obtained by many years of work on models of pathophysiology and pathogenesis and by many years of clinical research, including rapidly evolving noninvasive brain imaging; and third, on the broadening and refining of our analytical tools for animal models.
